Chai Discovery Raises $400 Million at $3.8 Billion Valuation
Updated
Updated · The New York Times · Jul 14
Chai Discovery Raises $400 Million at $3.8 Billion Valuation
2 articles · Updated · The New York Times · Jul 14
Summary
$400 million in new funding will be announced Tuesday by Chai Discovery, valuing the AI drug-design startup at $3.8 billion.
Index Ventures led the round, with Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Thrive Capital, OpenAI and Reed Jobs's Yosemite also participating.
The deal underscores continued investor appetite for specialized AI companies, particularly those using the technology to design breakthrough drugs rather than build general-purpose models.
AI drug discovery has already drawn heavy capital across the sector: Google spinoff Isomorphic Labs has raised $2.7 billion from investors since March 2025.
Is the AI drug discovery boom creating real cures or just a multi-billion dollar bubble?
When an AI designs a flawed drug, who is ultimately held responsible?
Chai Discovery’s $400 Million Raise and $3.8 Billion Valuation: AI Drug Discovery’s New Benchmark
Overview
Chai Discovery, founded in 2024 by a team with deep expertise in AI and molecular design, has rapidly emerged as a leader in AI-driven drug discovery. After closing a $130 million Series B round in December 2025 with a $1.3 billion valuation, the company announced a major $400 million funding round in July 2026, boosting its valuation to $3.8 billion. This swift growth reflects strong market confidence in Chai Discovery’s innovative approach, as it leverages advanced AI to revolutionize drug development and attract significant investment within just over six months.